Industry could have two tracks for proposing changes to OTC products marketed under the US monograph system: one for adding new medical conditions treated by the ingredients, which would be eligible for exclusivity when clinical trials are required, and another for most other types of changes.
The approach is proposed in a discussion draft of legislation to create a user fee program for OTC...